NCCN Categories of Evidence and Consensus
Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.
Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.
Category 2B: Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate.
Category 3: Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate.
All recommendations are category 2A unless otherwise noted.
Clinical trials: NCCN believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
Social Security Administration. Period Life Table. 2009. Available at: http://www.ssa.gov/OACT/STATS/table4c6.html. Accessed March 10, 2014.
D’Amico AV, Whittington R, Malkowicz SB et al.. Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J Clin Oncol 1999;17:168–172.
D’Amico AV, Whittington R, Malkowicz SB et al.. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer 2002;95:281–286.
D’Amico AV, Whittington R, Malkowicz SB et al.. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969–974.
Reese AC, Pierorazio PM, Han M, Partin AW. Contemporary evaluation of the National Comprehensive Cancer Network prostate cancer risk classification system. Urology 2012;80:1075–1079.
Johns Hopkins Medicine. The Partin Tables. Available at: http://urology.jhu.edu/prostate/partintables.php. Accessed March 24, 2014.
Makarov DV, Trock BJ, Humphreys EB et al.. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology 2007;69:1095–1101.
Kattan MW, Eastham JA, Wheeler TM et al.. Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol 2003;170:1792–1797.
Memorial Sloan-Kettering Cancer Center. Prostate Cancer Nomograms. Available at: http://www.mskcc.org/mskcc/html/10088.cfm. Accessed March 24, 2014.
Stephenson AJ, Scardino PT, Eastham JA et al.. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst 2006;98:715–717.
Stephenson AJ, Kattan MW, Eastham JA et al.. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol 2009;27:4300–4305.
Graefen M, Haese A, Pichlmeier U et al.. A validated strategy for side specific prediction of organ confined prostate cancer: a tool to select for nerve sparing radical prostatectomy. J Urol 2001;165:857–863.
Ohori M, Kattan MW, Koh H et al.. Predicting the presence and side of extracapsular extension: a nomogram for staging prostate cancer. J Urol 2004;171:1844–1849; discussion 1849.
Steuber T, Graefen M, Haese A et al.. Validation of a nomogram for prediction of side specific extracapsular extension at radical prostatectomy. J Urol 2006;175:939–944; discussion 944.
Briganti A, Chun FK, Salonia A et al.. A nomogram for staging of exclusive nonobturator lymph node metastases in men with localized prostate cancer. Eur Urol 2007;51:112–119; discussion 119-120.
Kattan MW, Potters L, Blasko JC et al.. Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer. Urology 2001;58:393–399.
Potters L, Morgenstern C, Calugaru E et al.. 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol 2008;179:S20–24.
Zelefsky MJ, Kattan MW, Fearn P et al.. Pretreatment nomogram predicting ten-year biochemical outcome of three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for prostate cancer. Urology 2007;70:283–287.
Jeldres C, Suardi N, Walz J et al.. Validation of the contemporary Epstein criteria for insignificant prostate cancer in European men. Eur Urol 2008;54:1306–1313.
Lee SJ, Lindquist K, Segal MR, Covinsky KE. Development and validation of a prognostic index for 4-year mortality in older adults. JAMA 2006;295:801–808.
Stephenson AJ, Scardino PT, Kattan MW et al.. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 2007;25:2035–2041.
Dearnaley DP, Khoo VS, Norman AR et al.. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial. Lancet 1999;353:267–272.
Khoo VS. Radiotherapeutic techniques for prostate cancer, dose escalation and brachytherapy. Clin Oncol (R Coll Radiol) 2005;17:560–571.
D’Amico AV, Cote K, Loffredo M et al.. Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol 2002;20:4567–4573.
D’Amico AV, Moul JW, Carroll PR et al.. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 2003;95:1376–1383.
Johansson JE, Holmberg L, Johansson S et al.. Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA 1997;277:467–471.
van den Bergh RC, Essink-Bot ML, Roobol MJ et al.. Anxiety and distress during active surveillance for early prostate cancer. Cancer 2009;115:3868–3878.
Sakr WA, Grignon DJ, Crissman JD et al.. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo 1994;8:439–443.
Thompson IM, Pauler DK, Goodman PJ et al.. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 2004;350:2239–2246.
Schroder FH, Hugosson J, Roobol MJ et al.. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320–1328.
Andriole GL, Crawford ED, Grubb RL 3rd et al.. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009;360:1310–1319.
Andriole GL, Crawford ED, Grubb RL 3rd et al.. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst 2012;104:125–132.
Hugosson J, Carlsson S, Aus G et al.. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010;11:725–732.
Miller DC, Gruber SB, Hollenbeck BK et al.. Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J Natl Cancer Inst 2006;98:1134–1141.
Draisma G, Etzioni R, Tsodikov A et al.. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst 2009;101:374–383.
Draisma G, Boer R, Otto SJ et al.. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003;95:868–878.
Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994;271:368–374.
Bastian PJ, Mangold LA, Epstein JI, Partin AW. Characteristics of insignificant clinical T1c prostate tumors: a contemporary analysis. Cancer 2004;101:2001–2005.
Chun FK, Haese A, Ahyai SA et al.. Critical assessment of tools to predict clinically insignificant prostate cancer at radical prostatectomy in contemporary men. Cancer 2008;113:701–709.
Bastian PJ, Carter BH, Bjartell A et al.. Insignificant prostate cancer and active surveillance: from definition to clinical implications. Eur Urol 2009;55:1321–1330.
Sanda MG, Kaplan ID. A 64-year-old man with low-risk prostate cancer: review of prostate cancer treatment. JAMA 2009;301:2141–2151.
Sundi D, Ross AE, Humphreys EB et al.. African American men with very low-risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: should active surveillance still be an option for them? J Clin Oncol 2013;31:2991–2997.
Carter HB, Kettermann A, Warlick C et al.. Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol 2007;178:2359–2364; discussion 2364-2355.
Dall’Era MA, Konety BR, Cowan JE et al.. Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer 2008;112:2664–2670.
Klotz L, Zhang L, Lam A et al.. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010;28:126–131.
Sheridan TB, Carter HB, Wang W et al.. Change in prostate cancer grade over time in men followed expectantly for stage T1c disease. J Urol 2008;179:901–904; discussion 904-905.
Tosoian JJ, Trock BJ, Landis P et al.. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol 2011;29:2185–2190.
Loblaw A, Zhang L, Lam A et al.. Comparing prostate specific antigen triggers for intervention in men with stable prostate cancer on active surveillance. J Urol 2010;184:1942–1946.
Ross AE, Loeb S, Landis P et al.. Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol 2010;28:2810–2816.
Feliciano J, Teper E, Ferrandino M et al.. The incidence of fluoroquinolone resistant infections after prostate biopsy: are fluoroquinolones still effective prophylaxis? J Urol 2008;179:952–955; discussion 955.
Fujita K, Landis P, McNeil BK, Pavlovich CP. Serial prostate biopsies are associated with an increased risk of erectile dysfunction in men with prostate cancer on active surveillance. J Urol 2009;182:2664–2669.
Bill-Axelson A, Holmberg L, Ruutu M et al.. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2011;364:1708–1717.
Pierorazio PM, Ross AE, Lin BM et al.. Preoperative characteristics of high-Gleason disease predictive of favourable pathological and clinical outcomes at radical prostatectomy. BJU Int 2012;110:1122–1128.
Chade DC, Eastham J, Graefen M et al.. Cancer control and functional outcomes of salvage radical prostatectomy for radiation-recurrent prostate cancer: a systematic review of the literature. Eur Urol 2012;61:961–971.
Klein EA, Bianco FJ, Serio AM et al.. Surgeon experience is strongly associated with biochemical recurrence after radical prostatectomy for all preoperative risk categories. J Urol 2008;179:2212–2216; discussion 2216-2217.
Smith JA Jr., Herrell SD. Robotic-assisted laparoscopic prostatectomy: do minimally invasive approaches offer significant advantages? J Clin Oncol 2005;23:8170–8175.
Hu JC, Gu X, Lipsitz SR et al.. Comparative effectiveness of minimally invasive vs open radical prostatectomy. JAMA 2009;302:1557–1564.
Ficarra V, Novara G, Rosen RC et al.. Systematic review and meta-analysis of studies reporting urinary continence recovery after robot-assisted radical prostatectomy. Eur Urol 2012;62:405–417.
Ficarra V, Novara G, Ahlering TE et al.. Systematic review and meta-analysis of studies reporting potency rates after robot-assisted radical prostatectomy. Eur Urol 2012;62:418–430.
Resnick MJ, Koyama T, Fan KH et al.. Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med 2013;368:436–445.
Nam RK, Cheung P, Herschorn S et al.. Incidence of complications other than urinary incontinence or erectile dysfunction after radical prostatectomy or radiotherapy for prostate cancer: a population-based cohort study. Lancet Oncol 2014;15:223–231.
Freire MP, Weinberg AC, Lei Y et al.. Anatomic bladder neck preservation during robotic-assisted laparoscopic radical prostatectomy: description of technique and outcomes. Eur Urol 2009;56:972–980.
Abel EJ, Masterson TA, Warner JN et al.. Nerve-sparing prostatectomy and urinary function: a prospective analysis using validated quality-of-life measures. Urology 2009;73:1336–1340.
Davis JW, Chang DW, Chevray P et al.. Randomized phase II trial evaluation of erectile function after attempted unilateral cavernous nerve-sparing retropubic radical prostatectomy with versus without unilateral sural nerve grafting for clinically localized prostate cancer. Eur Urol 2009;55:1135–1143.
- Search Google Scholar
- Export Citation
. Davis JW Chang DW Chevray P Randomized phase II trial evaluation of erectile function after attempted unilateral cavernous nerve-sparing retropubic radical prostatectomy with versus without unilateral sural nerve grafting for clinically localized prostate cancer. Eur Urol 2009; 55: 1135– 1143.
Cagiannos I, Karakiewicz P, Eastham JA et al.. A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. J Urol 2003;170:1798–1803.
Heidenreich A, Ohlmann CH, Polyakov S. Anatomical extent of pelvic lymphadenectomy in patients undergoing radical prostatectomy. Eur Urol 2007;52:29–37.
Masterson TA, Bianco FJ Jr., Vickers AJ et al.. The association between total and positive lymph node counts, and disease progression in clinically localized prostate cancer. J Urol 2006;175:1320–1324; discussion 1324-1325.
Joslyn SA, Konety BR. Impact of extent of lymphadenectomy on survival after radical prostatectomy for prostate cancer. Urology 2006;68:121–125.
Allaf ME, Palapattu GS, Trock BJ et al.. Anatomical extent of lymph node dissection: impact on men with clinically localized prostate cancer. J Urol 2004;172:1840–1844.
Bader P, Burkhard FC, Markwalder R, Studer UE. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? J Urol 2003;169:849–854.
Daneshmand S, Quek ML, Stein JP et al.. Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results. J Urol 2004;172:2252–2255.
Wagner M, Sokoloff M, Daneshmand S. The role of pelvic lymphadenectomy for prostate cancer—therapeutic? J Urol 2008;179:408–413.
Hanlon AL, Watkins Bruner D, Peter R, Hanks GE. Quality of life study in prostate cancer patients treated with three-dimensional conformal radiation therapy: comparing late bowel and bladder quality of life symptoms to that of the normal population. Int J Radiat Oncol Biol Phys 2001;49:51–59.
- Search Google Scholar
- Export Citation
. Hanlon AL Watkins Bruner D Peter R Hanks GE Quality of life study in prostate cancer patients treated with three-dimensional conformal radiation therapy: comparing late bowel and bladder quality of life symptoms to that of the normal population. Int J Radiat Oncol Biol Phys 2001; 49: 51– 59.
Koper PC, Stroom JC, van Putten WL et al.. Acute morbidity reduction using 3DCRT for prostate carcinoma: a randomized study. Int J Radiat Oncol Biol Phys 1999;43:727–734.
Michalski JM, Bae K, Roach M et al.. Long-term toxicity following 3D conformal radiation therapy for prostate cancer from the RTOG 9406 phase I/II dose escalation study. Int J Radiat Oncol Biol Phys 2010;76:14–22.
Jacobs BL, Zhang Y, Schroeck FR et al.. Use of advanced treatment technologies among men at low risk of dying from prostate cancer. JAMA 2013;309:2587–2595.
Zelefsky MJ, Levin EJ, Hunt M et al.. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008;70:1124–1129.
Jani AB, Su A, Correa D, Gratzle J. Comparison of late gastrointestinal and genitourinary toxicity of prostate cancer patients undergoing intensity-modulated versus conventional radiotherapy using localized fields. Prostate Cancer Prostatic Dis 2007;10:82–86.
Jacobs BL, Zhang Y, Skolarus TA et al.. Comparative effectiveness of external-beam radiation approaches for prostate cancer. Eur Urol 2014;65:162–168.
Peeters ST, Heemsbergen WD, Koper PC et al.. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 2006;24:1990–1996.
Pollack A, Zagars GK, Starkschall G et al.. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002;53:1097–1105.
Zietman AL, DeSilvio ML, Slater JD et al.. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 2005;294:1233–1239.
Kuban DA, Tucker SL, Dong L et al.. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008;70:67–74.
Xu N, Rossi PJ, Jani AB. Toxicity analysis of dose escalation from 75.6 gy to 81.0 gy in prostate cancer. Am J Clin Oncol 2011;34:11–15.
Eade TN, Hanlon AL, Horwitz EM et al.. What dose of external-beam radiation is high enough for prostate cancer? Int J Radiat Oncol Biol Phys 2007;68:682–689.
Pollack A, Walker G, Horwitz EM et al.. Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. J Clin Oncol 2013;31:3860–3868.
Arcangeli S, Strigari L, Gomellini S et al.. Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2012;84:1172–1178.
Potosky AL, Davis WW, Hoffman RM et al.. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst 2004;96:1358–1367.
Sanda MG, Dunn RL, Michalski J et al.. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008;358:1250–1261.
Nguyen PL, D’Amico AV, Lee AK, Suh WW. Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate-specific antigen failure: a systematic review of the literature. Cancer 2007;110:1417–1428.
Critz FA, Benton JB, Shrake P, Merlin ML. 25-Year disease-free survival rate after irradiation for prostate cancer calculated with the prostate specific antigen definition of recurrence used for radical prostatectomy. J Urol 2013;189:878–883.
Bolla M, Van Tienhoven G, Warde P et al.. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol 2010;11:1066–1073.
Pilepich MV, Winter K, Lawton CA et al.. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005;61:1285–1290.
Warde P, Mason M, Ding K et al.. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet 2011;378:2104–2111.
Widmark A, Klepp O, Solberg A et al.. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 2009;373:301–308.
Dasu A. Is the alpha/beta value for prostate tumours low enough to be safely used in clinical trials? Clin Oncol (R Coll Radiol) 2007;19:289–301.
Buyyounouski MK, Price RA Jr., Harris EE et al.. Stereotactic body radiotherapy for primary management of early-stage, low- to intermediate-risk prostate cancer: report of the American Society for Therapeutic Radiology and Oncology Emerging Technology Committee. Int J Radiat Oncol Biol Phys 2010;76:1297–1304.
- Search Google Scholar
- Export Citation
. Buyyounouski MK Price RA Jr. Harris EE Stereotactic body radiotherapy for primary management of early-stage, low- to intermediate-risk prostate cancer: report of the American Society for Therapeutic Radiology and Oncology Emerging Technology Committee. Int J Radiat Oncol Biol Phys 2010; 76: 1297– 1304.
Kang JK, Cho CK, Choi CW et al.. Image-guided stereotactic body radiation therapy for localized prostate cancer. Tumori 2011;97:43–48.
Madsen BL, Hsi RA, Pham HT et al.. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results. Int J Radiat Oncol Biol Phys 2007;67:1099–1105.
Chen LN, Suy S, Uhm S et al.. Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience. Radiat Oncol 2013;8:58.
Katz AJ, Santoro M, Diblasio F, Ashley R. Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years. Radiat Oncol 2013;8:118.
King CR, Freeman D, Kaplan I et al.. Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials. Radiother Oncol 2013;109:217–221.
Brachman DG, Thomas T, Hilbe J, Beyer DC. Failure-free survival following brachytherapy alone or external beam irradiation alone for T1-2 prostate tumors in 2222 patients: results from a single practice. Int J Radiat Oncol Biol Phys 2000;48:111–117.
Merrick GS, Butler WM, Wallner KE et al.. Permanent interstitial brachytherapy in younger patients with clinically organ-confined prostate cancer. Urology 2004;64:754–759.
Eade TN, Horwitz EM, Ruth K et al.. A comparison of acute and chronic toxicity for men with low-risk prostate cancer treated with intensity-modulated radiation therapy or (125)I permanent implant. Int J Radiat Oncol Biol Phys 2008;71:338–345.
Wong WW, Vora SA, Schild SE et al.. Radiation dose escalation for localized prostate cancer: intensity-modulated radiotherapy versus permanent transperineal brachytherapy. Cancer 2009;115:5596–5606.
Lee N, Wuu CS, Brody R et al.. Factors predicting for postimplantation urinary retention after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2000;48:1457–1460.
Henkel TO, Kahmann F. Permanent brachytherapy: prostate seed implants as an out-patient treatment. Arch Ital Urol Androl 2000;72:295–301.
Nag S, Bice W, DeWyngaert K et al.. The American Brachytherapy Society recommendations for permanent prostate brachytherapy postimplant dosimetric analysis. Int J Radiat Oncol Biol Phys 2000;46:221–230.
Al-Salihi O, Mitra A, Payne H. Challenge of dose escalation in locally advanced unfavourable prostate cancer using HDR brachytherapy. Prostate Cancer Prostatic Dis 2006;9:370–373.
Fang FM, Wang YM, Wang CJ et al.. Comparison of the outcome and morbidity for localized or locally advanced prostate cancer treated by high-dose-rate brachytherapy plus external beam radiotherapy (EBRT) versus EBRT alone. Jpn J Clin Oncol 2008;38:474–479.
Pieters BR, van de Kamer JB, van Herten YR et al.. Comparison of biologically equivalent dose-volume parameters for the treatment of prostate cancer with concomitant boost IMRT versus IMRT combined with brachytherapy. Radiother Oncol 2008;88:46–52.
Soumarova R, Homola L, Perkova H, Stursa M. Three-dimensional conformal external beam radiotherapy versus the combination of external radiotherapy with high-dose rate brachytherapy in localized carcinoma of the prostate: comparison of acute toxicity. Tumori 2007;93:37–44.
- Search Google Scholar
- Export Citation
. Soumarova R Homola L Perkova H Stursa M Three-dimensional conformal external beam radiotherapy versus the combination of external radiotherapy with high-dose rate brachytherapy in localized carcinoma of the prostate: comparison of acute toxicity. Tumori 2007; 93: 37– 44.
Sathya JR, Davis IR, Julian JA et al.. Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. J Clin Oncol 2005;23:1192–1199.
Hoskin PJ, Motohashi K, Bownes P et al.. High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: initial results of a randomised phase three trial. Radiother Oncol 2007;84:114–120.
Hoskin PJ, Rojas AM, Bownes PJ et al.. Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer. Radiother Oncol 2012;103:217–222.
Shen X, Keith SW, Mishra MV et al.. The impact of brachytherapy on prostate cancer-specific mortality for definitive radiation therapy of high-grade prostate cancer: a population-based analysis. Int J Radiat Oncol Biol Phys 2012;83:1154–1159.
Bittner N, Merrick GS, Butler WM et al.. Long-term outcome for very high-risk prostate cancer treated primarily with a triple modality approach to include permanent interstitial brachytherapy. Brachytherapy 2012;11:250–255.
Martinez-Monge R, Moreno M, Ciervide R et al.. External-beam radiation therapy and high-dose rate brachytherapy combined with long-term androgen deprivation therapy in high and very high prostate cancer: preliminary data on clinical outcome. Int J Radiat Oncol Biol Phys 2012;82:e469–476.
- Search Google Scholar
- Export Citation
. Martinez-Monge R Moreno M Ciervide R External-beam radiation therapy and high-dose rate brachytherapy combined with long-term androgen deprivation therapy in high and very high prostate cancer: preliminary data on clinical outcome. Int J Radiat Oncol Biol Phys 2012; 82: e469– 476.
D’Amico AV, Moran BJ, Braccioforte MH et al.. Risk of death from prostate cancer after brachytherapy alone or with radiation, androgen suppression therapy, or both in men with high-risk disease. J Clin Oncol 2009;27:3923–3928.
Demanes DJ, Brandt D, Schour L, Hill DR. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation. Am J Clin Oncol 2009;32:342–347.
Dattoli M, Wallner K, True L et al.. Long-term outcomes for patients with prostate cancer having intermediate and high-risk disease, treated with combination external beam irradiation and brachytherapy. J Oncol 2010;2010:471375.
Grills IS, Martinez AA, Hollander M et al.. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds. J Urol 2004;171:1098–1104.
Vargas C, Ghilezan M, Hollander M et al.. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy. J Urol 2005;174:882–887.
Yu JB, Soulos PR, Herrin J et al.. Proton versus intensity-modulated radiotherapy for prostate cancer: patterns of care and early toxicity. J Natl Cancer Inst 2013;105:25–32.
Coen JJ, Paly JJ, Niemierko A et al.. Long-term quality of life outcome after proton beam monotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2012;82:e201–209.
Allen AM, Pawlicki T, Dong L et al.. An evidence based review of proton beam therapy: the report of ASTRO’s emerging technology committee. Radiother Oncol 2012;103:8–11.
Babaian RJ, Donnelly B, Bahn D et al.. Best practice statement on cryosurgery for the treatment of localized prostate cancer. J Urol 2008;180:1993–2004.
Bahn D, de Castro Abreu AL, Gill IS et al.. Focal cryotherapy for clinically unilateral, low-intermediate risk prostate cancer in 73 men with a median follow-up of 3.7 years. Eur Urol 2012;62:55–63.
Donnelly BJ, Saliken JC, Brasher PM et al.. A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer. Cancer 2010;116:323–330.
Robinson JW, Donnelly BJ, Siever JE et al.. A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer: quality of life outcomes. Cancer 2009;115:4695–4704.
Chin JL, Al-Zahrani AA, Autran-Gomez AM et al.. Extended followup oncologic outcome of randomized trial between cryoablation and external beam therapy for locally advanced prostate cancer (T2c-T3b). J Urol 2012;188:1170–1175.
Barret E, Ahallal Y, Sanchez-Salas R et al.. Morbidity of focal therapy in the treatment of localized prostate cancer. Eur Urol 2013;63:618–622.
Lu-Yao GL, Albertsen PC, Moore DF et al.. Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA 2008;300:173–181.
D’Amico AV, Chen MH, Renshaw AA et al.. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA 2008;299:289–295.
Denham JW, Steigler A, Lamb DS et al.. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol 2011;12:451–459.
Jones CU, Hunt D, McGowan DG et al.. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med 2011;365:107–118.
Roach M 3rd, Bae K, Speight J et al.. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol 2008;26:585–591.
Horwitz EM, Bae K, Hanks GE et al.. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 2008;26:2497–2504.
Bolla M, de Reijke TM, Van Tienhoven G et al.. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009;360:2516–2527.
Souhami L, Bae K, Pilepich M, Sandler H. Impact of the duration of adjuvant hormonal therapy in patients with locally advanced prostate cancer treated with radiotherapy: a secondary analysis of RTOG 85-31. J Clin Oncol 2009;27:2137–2143.
Kumar S, Shelley M, Harrison C et al.. Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst Rev 2006:CD006019.
Messing EM, Manola J, Yao J et al.. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006;7:472–479.
Loblaw DA, Virgo KS, Nam R et al.. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2007;25:1596–1605.
Wong YN, Freedland S, Egleston B et al.. Role of androgen deprivation therapy for node-positive prostate cancer. J Clin Oncol 2009;27:100–105.
McLeod DG, Iversen P, See WA et al.. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int 2006;97:247–254.
McLeod DG, See WA, Klimberg I et al.. The bicalutamide 150 mg early prostate cancer program: findings of the North American trial at 7.7-year median followup. J Urol 2006;176:75–80.
Briganti A, Passoni N, Ferrari M et al.. When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of the currently available guidelines and proposal of a novel risk stratification tool. Eur Urol 2010;57:551–558.
Wolf JS Jr., Cher M, Dall’era M et al.. The use and accuracy of cross-sectional imaging and fine needle aspiration cytology for detection of pelvic lymph node metastases before radical prostatectomy. J Urol 1995;153:993–999.
Dickinson L, Ahmed HU, Allen C et al.. Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. Eur Urol 2011;59:477–494.
Dall’Era MA, Albertsen PC, Bangma C et al.. Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol 2012;62:976–983.
Pound CR, Partin AW, Eisenberger MA et al.. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591–1597.
Thompson IM, Tangen CM, Paradelo J et al.. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 2009;181:956–962.
Thompson IM Jr., Tangen CM, Paradelo J et al.. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 2006;296:2329–2335.
Swanson GP, Goldman B, Tangen CM et al.. The prognostic impact of seminal vesicle involvement found at prostatectomy and the effects of adjuvant radiation: data from Southwest Oncology Group 8794. J Urol 2008;180:2453–2457; discussion 2458.
Van der Kwast TH, Bolla M, Van Poppel H et al.. Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. J Clin Oncol 2007;25:4178–4186.
Wiegel T, Bottke D, Steiner U et al.. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 2009;27:2924–2930.
- Search Google Scholar
- Export Citation
. Wiegel T Bottke D Steiner U Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 2009; 27: 2924– 2930.
Da Pozzo LF, Cozzarini C, Briganti A et al.. Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy. Eur Urol 2009;55:1003–1011.